Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity.
Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity.
复制标题
基于粪便的菌群菌群疗法，用于复发性艰难梭菌感染，溃疡性结肠炎和肥胖症。
DOI：
10.1016/j.ebiom.2016.09.029
复制
发表时间：
2016-11
期刊：
影响因子：
11.1
通讯作者：
Allen-Vercoe E
中科院分区：
文献类型：
--
作者：
Carlucci C;Petrof EO;Allen-Vercoe E
人体肠道微生物群是一个对人类健康至关重要的复杂生态系统。我们对肠道微生物组成和健康和疾病状态下功能相互作用的了解不断加深，这促使了研究努力，将肠道微生物群作为治疗干预的有价值的目标。该综述提供了艰难梭菌感染(CDI)、溃疡性结肠炎(UC)和肥胖症患者肠道微生物群状态的最新研究进展，同时阐述了使用基于粪便微生物区系移植(FMT)的治疗来调节肠道微生物群的基本原理。讨论了目前基于微生物组的治疗在临床前或临床开发中的情况。最后，我们将这放在目前围绕FMT和相关疗法的监管框架的背景下。在健康和疾病状态下，对肠道微生物组成和功能相互作用的了解越来越多。FMT对RCDI有效，并已导致基于粪便微生物群的治疗方法的发展，用于其他适应症。要使大便替代疗法进入主流医学，还需要进一步的机制研究、随机对照试验和法规。
The human gut microbiome is a complex ecosystem of fundamental importance to human health. Our increased understanding of gut microbial composition and functional interactions in health and disease states has spurred research efforts examining the gut microbiome as a valuable target for therapeutic intervention. This review provides updated insight into the state of the gut microbiome in recurrent Clostridium difficile infection (CDI), ulcerative colitis (UC), and obesity while addressing the rationale for the modulation of the gut microbiome using fecal microbiota transplant (FMT)-based therapies. Current microbiome-based therapeutics in pre-clinical or clinical development are discussed. We end by putting this within the context of the current regulatory framework surrounding FMT and related therapies. There is an increased understanding of gut microbial composition and functional interactions in health and disease states. FMT is effective for rCDI and has led to the development of fecal microbiota-based therapeutics for other indications. For stool-substitute therapies to enter mainstream medicine, further mechanistic studies, RCTs and regulations are needed.